William Blair Reaffirms “Outperform” Rating for IQVIA (NYSE:IQV)

IQVIA (NYSE:IQV)‘s stock had its “outperform” rating reiterated by equities research analysts at William Blair in a research note issued to investors on Wednesday,RTT News reports.

A number of other brokerages have also issued reports on IQV. Truist Financial dropped their target price on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Redburn Atlantic assumed coverage on shares of IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 price objective for the company. BTIG Research lowered their price target on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Barclays decreased their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Finally, Morgan Stanley decreased their price target on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Five analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $256.50.

IQVIA Price Performance

NYSE IQV opened at $203.31 on Wednesday. The stock has a market capitalization of $36.90 billion, a PE ratio of 26.68, a P/E/G ratio of 2.08 and a beta of 1.49. The stock has a 50-day simple moving average of $214.57 and a 200 day simple moving average of $224.96. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. IQVIA has a twelve month low of $187.62 and a twelve month high of $261.73.

Institutional Investors Weigh In On IQVIA

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Simplify Asset Management Inc. grew its holdings in shares of IQVIA by 67.8% during the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after purchasing an additional 3,894 shares during the last quarter. Raymond James & Associates increased its position in IQVIA by 0.7% in the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock valued at $169,231,000 after acquiring an additional 5,417 shares in the last quarter. Versor Investments LP bought a new position in shares of IQVIA in the third quarter worth about $1,328,000. Gradient Investments LLC lifted its position in shares of IQVIA by 15.6% during the second quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company’s stock worth $9,600,000 after purchasing an additional 6,134 shares in the last quarter. Finally, CIBC Asset Management Inc grew its stake in shares of IQVIA by 3.3% during the third quarter. CIBC Asset Management Inc now owns 263,752 shares of the medical research company’s stock valued at $62,501,000 after purchasing an additional 8,490 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.